⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 28, 2025Future Oncology

Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study

View at Publisher

Ask AI

Bookmark

Share

Abstract

Ruxolitinib demonstrated sustained effectiveness with no new safety concerns in the real-world setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Weizhe Lu (2025) studied this question.

synapsesocial.com/papers/69402e042d562116f290456b https://doi.org/10.1080/14796694.2025.2595691

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study2025 · 6 citations
2Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)Cohort Study · 2026
3Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice2024 · 5 citations
4Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit controlLate-Phase Clinical Trial · 2026 · 1 citations
5Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study2024 · 2 citations

More related papers

Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman2026
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls2012
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)2026

More from Future Oncology

First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysisMon,
Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trialWed,